KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Gross Margin (2020 - 2023)

AbCellera Biologics' Gross Margin history spans 4 years, with the latest figure at 66.23% for Q4 2023.

  • For the quarter ending Q4 2023, Gross Margin fell 2681.0% year-over-year to 66.23%, compared with a TTM value of 71.83% through Dec 2023, down 2363.0%, and an annual FY2024 reading of 55.68%, down 703.0% over the prior year.
  • Gross Margin for Q4 2023 was 66.23% at AbCellera Biologics, down from 100.0% in the prior quarter.
  • The five-year high for Gross Margin was 100.0% in Q3 2023, with the low at 61.8% in Q2 2023.
  • Average Gross Margin over 4 years is 87.3%, with a median of 91.83% recorded in 2020.
  • Biggest YoY gain for Gross Margin was 1483bps in 2023; the steepest drop was -3140bps in 2023.
  • Tracing ABCL's Gross Margin over 4 years: stood at 87.74% in 2020, then grew by 12bps to 98.69% in 2021, then dropped by -6bps to 93.04% in 2022, then dropped by -29bps to 66.23% in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Gross Margin are 66.23% (Q4 2023), 100.0% (Q3 2023), and 61.8% (Q2 2023).